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Overcoming acquired resistance to HSP90
inhibition by targeting JAK-STAT signalling
in triple-negative breast cancer
Nuramalina H. Mumin1, Neele Drobnitzky1, Agata Patel1, Luiza Madia Lourenco1, Fiona F. Cahill1, Yanyan Jiang1,
Anthony Kong2 and Anderson J. Ryan1*
Abstract
Background: Due to the lack of effective therapies and poor prognosis in TNBC (triple-negative breast cancer)
patients, there is a strong need to develop effective novel targeted therapies for this subtype of breast cancer.
Inhibition of heat shock protein 90 (HSP90), a conserved molecular chaperone that is involved in the regulation
of oncogenic client proteins, has shown to be a promising therapeutic approach for TNBC. However, both intrinsic
and acquired resistance to HSP90 inhibitors (HSP90i) limits their effectiveness in cancer patients.
Methods: We developed models of acquired resistance to HSP90i by prolonged exposure of TNBC cells to HSP90i
(ganetespib) in vitro. Whole transcriptome profiling and a 328-compound bioactive small molecule screen were
performed on these cells to identify the molecular basis of acquired resistance to HSP90i and potential therapeutic
approaches to overcome resistance.
Results: Among a panel of seven TNBC cell lines, the most sensitive cell line (Hs578T) to HSP90i was selected as an
in vitro model to investigate acquired resistance to HSP90i. Two independent HSP90i-resistant clones were successfully
isolated which both showed absence of client proteins degradation, apoptosis induction and G2/M cell cycle arrest
after treatment with HSP90i. Gene expression profiling and pathway enrichment analysis demonstrate significant
activation of the survival JAK-STAT signalling pathway in both HSP90i-resistant clones, possibly through IL6 autocrine
signalling. A bioactive small molecule screen also demonstrated that the HSP90i-resistant clones showed selective
sensitivity to JAK2 inhibition. Inhibition of JAK and HSP90 caused higher induction of apoptosis, despite prior acquired
resistance to HSP90i.
Conclusions: Acquired resistance to HSP90i in TNBC cells is associated with an upregulated JAK-STAT signalling
pathway. A combined inhibition of the JAK-STAT signalling pathway and HSP90 could overcome this resistance. The
benefits of the combined therapy could be explored further for the development of effective targeted therapy in TNBC
patients.
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Background
Triple-negative breast cancer (TNBC), which accounts for
about 10% of all breast cancer cases, is defined by the
absence of ER (estrogen receptor) and PR (progesterone
receptor) expression, together with lack of HER2 (human
epidermal growth factor 2 receptor) gene amplification or
protein overexpression at diagnosis. TNBC is often associ-
ated with younger age (< 50) and more common in
African-American women [1–3]. The tumours are gener-
ally larger in size, more aggressive, of higher grade and
have propensity of lymph node involvement [4].
Chemotherapy is the only effective systemic treatment
option for TNBC patients. Although TNBC patients
have a significantly higher complete response rate to
neoadjuvant chemotherapy compared to other breast
cancer subtypes, TNBC patients have lower rates of
progression-free survival and overall survival within the
first 3 years [5]. After chemotherapy, TNBC patients
with residual disease have a significantly worse overall
survival compared to other breast cancer subtypes dis-
playing residual disease [5]. Due to the lack of approved
targeted therapies and poor prognosis in TNBC patients,
there is an urgent need to develop effective treatments
for this subtype of breast cancer.
High expression of HSP90 (heat shock protein 90) is as-
sociated with poor prognosis and worse recurrence-free
survival in breast cancer patients, including TNBC pa-
tients [6–8]. HSP90 is a conserved molecular chaperone
that regulates the stability, activation and maturation of
more than 200 client proteins including receptor tyrosine
kinases (HER2, EGFR, IGF-1R, MET), transcription
factors (HIF1, TP53), signalling proteins (AKT, SRC) and
cell cycle regulatory proteins (CDK4, CDK6). Since HSP90
client proteins play key roles in the biological hallmarks of
cancer, targeting HSP90 provides the prospect of disrupt-
ing multiple oncogenic pathways simultaneously [9–12].
HSP90 was first identified as a therapeutic target when
treatment with natural product compounds, geldanamycin
and radicicol, decreased the levels of oncogenic client pro-
teins (SRC, HER2) by destabilising the HSP90-client protein
complex and directing it for ubiquitin-mediated proteoso-
mal degradation [13–15]. Several preclinical studies with
HSP90 inhibitors demonstrated effective anti-cancer activ-
ities at tolerable doses, where simultaneous degradation of
oncogenic client proteins and inhibition of tumour growth
were observed in multiple cancer models, including ovar-
ian, prostate and breast cancer [16–18]. HSP90 inhibitors
also showed tumour selectivity as they had higher binding
affinity to HSP90 from tumours compared to normal tissue,
and were accumulated in tumours and cleared rapidly from
blood and normal tissues in vivo [19, 20].
Ganetespib was the most advanced HSP90 inhibitor in
clinical development, when it entered Phase III clinical
trial in non-small cell lung cancer in combination with
docetaxel (NCT01798485). Patients were given ganete-
spib (150 mg/m2) and docetaxel (75 mg/m2) at Day 1
and ganetespib only at Day 15 of each 3-week treatment
cycle. Although the trial showed no benefit, the study
was performed in unselected patients. Ganetespib is a
resorcinol-based HSP90 inhibitor that has a unique tria-
zolone moiety and lacks the benzoquinone chemical
moiety, which is often associated with the dose-limiting
hepatotoxicity of geldanamycin-derived HSP90 inhibi-
tors [21–23]. Ganetespib demonstrated higher in vitro
potency, greater anti-cancer activity, and more efficient
distribution in tumours without causing serious toxicity
(liver, cardiac and ocular) [23–25]. In TNBC, ganetespib
caused the downregulation of multiple client proteins
(EGFR, IGF-1R, MET and CRAF), G2/M phase cell
cycle arrest, inhibition of metastasis and tumour
growth [26, 27]. In clinical trials, HSP90 inhibitors
have shown evidence of anti-tumour activities in pa-
tients with HER2-positive breast cancer and TNBC
disease [28–31]. Despite these encouraging clinical re-
sponses, they were short-lived and not all patients
responded to the treatment, suggesting that resistance
to HSP90 inhibition (HSP90i) develops in breast can-
cer patients.
The mechanisms of resistance to HSP90i in TNBC are
not yet understood. A greater understanding of these re-
sistance mechanisms should help to identify potential
predictive biomarkers for a better selection of responsive
patients to HSP90i therapy and help in the development
of effective therapeutics for TNBC patients. In this
study, whole transcriptome profiling and a bioactive
small molecule screen were performed on TNBC cells
with acquired resistance to HSP90i to identify the mo-
lecular basis of their resistance and potential therapeutic
approaches to overcome it.
Methods
Cell culture and reagents
MDA-MB-231, MDA-MB-468 and MDA-MB-453 cell lines
were obtained from the American Type Culture Collection.
HCC-1143, HCC-1937 and Hs578T cell lines were obtained
from Dr. P McGowan (St Vincent’s University Hospital,
Ireland) while BT-20 cell line was obtained from Professor
Adrian Harris (University of Oxford, UK). MDA-MB-453,
MDA-MB-468, MDA-MB-231, Hs578T and BT-20 cell lines
were maintained in DMEM (Dulbecco’s modified Eagle
medium; Life Technologies), supplemented with 10% (v/v)
foetal bovine serum (FBS; Sigma-Aldrich), 2mM GlutaMax
(Life Technologies) and 50U penicillin/ 50 μg/ml strepto-
mycin (Life Technologies). HCC-1143 and HCC-1937 cell
lines were maintained in RPMI-1640 medium (Life
Technologies), supplemented with 10% (v/v) FBS, 2mM
GlutaMax and 50U penicillin/ 50 μg/ml streptomycin. The
cell lines were authenticated using Short Tandem Repeat
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(STR) analysis and tested for Mycoplasma infection using
PCR, as described in [32].
Ganetespib and a 326-compound bioactive small molecule
library (L1100), including 17-AAG and NVP-AUY922, were
obtained from Selleckchem (USA). All stock solutions were
prepared DMSO and stored at − 20 °C.
Generation of ganetespib resistant clones
Hs578T cells were plated onto 10 cm dishes (106 cells
per plate) and after 3 days exposed to 30 nM ganetespib.
Fresh complete culture medium with ganetespib was
replaced at least once a week. After 6 weeks, colonies
formed on the plates (0–10 colonies per plate). Inde-
pendent colonies from separate plates were isolated
using cloning cylinders (Sigma-Aldrich, #C1059). The
clones were maintained in culture with the continuous
presence of 30 nM ganetespib. The clones remained
stably resistant to ganetespib even after culturing for 2
weeks in ganetespib-free medium.
Cell viability assay
Cell viability was assessed using a resazurin-based assay.
Cells were seeded in triplicates in 96-well plate and
treated the next day with indicated compound or com-
bination of compounds for 72 h (hr). A range of drug
concentrations was used by performing serial dilutions
with complete culture medium. After treatment,
resazurin solution was added into each well to a final
concentration of 12.5 μg/ml and incubated for 2 h. The
metabolically active viable cells reduce the resazurin to
highly fluorescent resorufin. The fluorescence intensity
(excitation 544 nm; emission at 590 nm) was measured
using a POLARstar Omega plate reader (BMG Labtech
GmbH, Germany). After subtracting the average fluores-
cence intensity of blank (medium, no cells) from the
wells, the fluorescence intensity was proportional to the
number of viable cells. The percent cell viability after
each treatment was normalised either to DMSO-treated
control or to cells treated at the fixed concentration of
compound alone for combination treatment. IC50 (the
drug concentration that reduces cell viability to 50% of
control) was calculated from three independent experi-
ments, each with triplicates measurements, using the
Origin software (OriginLab Corporation, USA).
Western blotting
Cells were seeded in 10 cm plates and treated the next day
with indicated compound or combination of compounds
for 24 h. After treatment, cells including in medium were
collected, washed twice with ice-cold PBS and lysed in
ice-cold lysis buffer containing 50mM Tris-HCl
(Promega, USA) (pH 7.6), 137mM NaCl (Sigma-Aldrich),
10% (v/v) glycerol (VWR, USA), 0.1% (v/v) Igepal
(Sigma-Aldrich), 0.1% (v/v) SDS (AppliChem GmbH,
Germany), 50mM sodium fluoride (Sigma-Aldrich), 1
mM sodium orthovanadate and cOmplete protease inhibi-
tor cocktail (Roche, Switzerland). The cell suspension was
left on ice for 30min (min) before brief sonication (twice
for 10 s) with a Bioruptor® Plus (Diagenode Inc., Belgium).
The cells were centrifuged at 16,100 x g for 10min at 4 °C
and supernatants containing soluble proteins were col-
lected for subsequent experiments.
Equal concentration of protein lysates were prepared
in sample buffer containing 25mM Tris-Base (Sigma-Al-
drich) (pH 6.8), 1% (v/v) SDS, 1 mM AccuGENE EDTA
(Lonza), 2.5% (v/v) β-mercaptoethanol (Sigma-Aldrich)
and 0.25 mg/ml Bromophenol blue (Acros organics,
USA), and the prepared lysates were heated to 95 °C for
8 min. The protein lysates (30–50 μg) were resolved onto
a 4–15% gradient precast TGX gel, transferred to a
PVDF membrane (0.45 μM pore size, Millipore), blocked
in TBS (Tris-buffered saline) with 5% (w/v) non-fat
skimmed milk (Sigma-Aldrich) and probed overnight
with the appropriate primary antibodies prepared in 5%
(w/v) non-fat skimmed milk in TBST (TBS with 0.1% (v/
v) Tween 20). The membranes were incubated with
horseradish peroxidase (HRP)-conjugated secondary
antibodies prepared in TBST-5% (w/v) non-fat skimmed
milk, and then ECL western blotting substrate was
added onto the membranes and protein signals were
visualised by chemiluminescence on a ChemiDoc MP
Imaging System (Bio-Rad). Antibodies used: were from
Cell Signaling (total EGFR, #2232, 1:1000; total AKT
#9272, 1:1000; phospho-AKT S473 #9271, 1:500; HSP90
#4877, 1:1000; HSP70 #4876, 1:500; PARP #9542, 1:2000;
total STAT3; #4904, 1:1000; phospho-STAT3 Y705;
#9131, 1:500), Sigma-Aldrich (β-actin, #A1978, 1:5000),
Abcam (Cyclophilin B (PPIB), #ab16045, 1:5000) or Invi-
trogen (phospho-EGFR Y1068, #44788G, 1:500).
Cell cycle analysis
Cells were seeded in duplicate in 10 cm plates and
treated the next day with indicated compound for 24 h.
20 min before the end of treatment, cells were pulse
labelled with 20 μM Bromodeoxyuridine (BrdU; Sigma-
Aldrich) and protected from light. After treatment, the
cells on the plate including in the medium were col-
lected and centrifuged at 280 x g for 5 min. Cell pellets
were washed with PBS and fixed by addition dropwise of
ice-cold ethanol (70% v/v, Sigma-Aldrich) while vor-
texing. The cells were incubated on ice for 30 min,
centrifuged at 280 x g for 5 min and resuspended in 2M
HCl (Fisher Scientific) containing 0.1 mg/ml pepsin
(Sigma-Aldrich). After incubation for 20 min and centri-
fugation, the cell pellets were washed twice with PBS,
once with PBS-2% (v/v) FBS and were later probed for
90 min with mouse anti-BrdU antibody (BD Biosciences,
#347580, 1:100) prepared in PBS-2% FBS. Cells were
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washed once with PBS-2% FBS and incubated with goat
anti-mouse Alexa Fluor® 488 secondary antibody (Life
Technologies, 1:200) prepared in PBS-2% FBS for 1 h in
the dark. Cells were washed once with PBS and stained
with 20 μg/ml of propidium iodide (PI) (Calbiochem) pre-
pared in PBS. Cells in S-phase (BrdU staining) and DNA
content (PI staining) were assessed using FACScan Flow
Cytometer (BD Biosciences) and BD CellQuest Pro soft-
ware. Cell cycle distributions (G0/G1-, S- and G2/M-
phases) were determined using ModFit LT (Verity Software
House, USA) and FlowJo software (Tree Star Inc., USA).
RNA sequencing
Parental Hs578T cell line and ganetespib-resistant clones
were seeded in 10 cm plates and treated the next day with
30 nM ganetespib or DMSO control for 24 h. After treat-
ment, cells were collected and RNA was isolated using the
RNeasy® Plus Mini Kit (Qiagen). Duplicate samples (1 μg
RNA in 30 μl) were subjected to RNA Sequencing (RNA--
seq) analysis (Oxford Gene Technology) and gene expres-
sion was quantified using their analysis pipeline [33].
Briefly, mRNAs were first isolated from the RNA samples
and libraries for sequencing were prepared using an RNA
Sample Prep Kit (TruSeq v2, Illumina). Paired-end sequen-
cing was performed using HiSeq2000 platform (Illumina)
and the sequencing reads were mapped onto the human
genome (GRCh37) using Bowtie (http://bowtie-bio.source-
forge.net/index.shtml/) and splice junctions were identified
using TopHat (http://ccb.jhu.edu/software/tophat/
index.shtml). The mapped reads were assembled to tran-
scripts and aligned (Cufflinks, http://cole-trapnell-lab.githu-
b.io/cufflinks//) for differential gene expression between
samples. The differential gene expressions were expressed
in log2 fold change (FC) and they were considered statis-
tical significant with q-value ≤0.05. Q-value is an adjusted
p-value that takes into account the false discovery rate
within the positive test. Pathway enrichment analysis was
performed on differentially expressed genes in the cells
using MetaCore (https://portal.genego.com, accessed Au-
gust 2016) (Thomson Reuters, USA).
Enzyme-linked immunosorbent assay (ELISA)
Cells were seeded in 96-well plate and treated the next day
with 30 nM ganetespib or DMSO control for 24 h. After
treatment, the media from the wells were collected and
enzyme-linked immunosorbent assay (ELISA) was per-
formed to measure the amount of IL6 in the media using
the Quantikine ELISA Human IL6 kit (R&D Systems).
Bioactive small molecule screen
A library (n = 328) containing 326 bioactive small mol-
ecule compounds (Selleck, L1100), was used in the
screen. The library was distributed into four 96-well
plates and each plate also contained wells with DMSO.
Ganetespib-resistant clone CR3 cells were seeded into
96-well plates and treated the next day with the indi-
cated compounds (final concentration of 1 μM), in the
absence or presence of 10 nM ganetespib for 72 h. Each
plate was set up in duplicate and the entire screen was
performed twice. Cell viability (resazurin-based assay)
was the screening end point.
The percentage cell viability after each treatment of
compound was first calculated relative to the average
DMSO-treated control in each plate. The average per-
centage cell viability from the two independent runs per-
formed in duplicates was then normalised to the overall
mean percentage of cell viability from the entire screen
for the respective cell line condition (absence or pres-
ence of ganetespib). In order to compare the sensitivity
(Z-score) of each compound between the two condi-
tions, the log value of the cell viability to each
compound between the cell lines was calculated and
normalised to the standard deviation of the entire
screen. Z-score ≥ 2 showed that the compound was se-
lectively cytotoxic in CR3 with the presence of ganete-
spib while Z-score ≤ − 2 showed that the compound was
selectively cytotoxic in CR3 with the absence of
ganetespib.
Statistical analysis
GraphPad Prism® 7 (GraphPad Software, USA) was used
for all statistical analyses and to generate graphs inclu-
ding heatmaps. For data comparison between cell lines
and treatment conditions, two-way analysis of variance
(ANOVA) was used. For comparison between two
groups, Student’s t-test was used. Statistical significance
of p-values ≤0.05, ≤ 0.01, ≤ 0.001, ≤0.0001 were repre-
sented as *, **, ***, **** respectively.
Results
In vitro model of acquired HSP90i-resistant TNBC cell line
Ganetespib is highly potent in a panel of seven TNBC
cell lines, with IC50 values range of 4 nM to 30 nM
(Fig. 1a). Exposure to increasing concentrations of gane-
tespib resulted in a dose-dependent downregulation of
HSP90 client proteins (EGFR and AKT) and their
phosphorylation state in the TNBC cell lines (Fig. 1b).
As expected, a pharmacodynamic marker of HSP90i,
HSP70 expression was upregulated in the cell lines after
the treatment. An increased level of cleaved PARP ex-
pression was also observed in these cells indicating an
induction of apoptosis after HSP90i. Apoptosis induction
was associated with ganetespib sensitivity in these cells,
where the most sensitive TNBC cell line, Hs578T cells,
showed higher induction of apoptosis after ganetespib
treatment compared to MDA-MB-231 and HCC1143
cells. These data demonstrate that HSP90i has anti-can-
cer activity in TNBC in vitro.
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Fig. 1 (See legend on next page.)
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To investigate the mechanisms of resistance to ganete-
spib, two independent clones were isolated by exposing
the most sensitive cell line Hs578T, with IC50 value of
4.79 ± 0.32 nM, to a high concentration of ganetespib
(30 nM) for 6 weeks (Fig. 1c). Both clones CR2 and CR3
were resistant to ganetespib with IC50 values 4- to 5-
fold higher than parental Hs578T cells (15.57 ± 1.90 nM
and 20.28 ± 2.75 nM respectively) (Fig. 2a). Interestingly,
they also showed cross-resistance to other HSP90i;
NVP-AUY922 and 17-AAG with similar or higher IC50
(Fig. 2a), further suggesting that both clones have ac-
quired resistance to HSP90i.
Compared to the parental Hs578T cells, the levels of
total and phosphorylated EGFR and AKT proteins in the
HSP90i-resistant clones were maintained and there was
absence of apoptosis induction after exposure to ganete-
spib (Fig. 2b). However, upregulation of HSP70 expres-
sion levels were observed in the HSP90i-resistant clones
after treatment, which further suggested that the
compound was pharmacologically active but the clones
were able to escape the inhibitory effects of ganetespib.
Flow cytometry analysis also demonstrated that the
HSP90i-resistant clones were able to escape the G2/M
cell cycle arrest caused by HSP90i. Only the parental
Hs578T cells but not the HSP90i-resistant CR2 and CR3
clones that showed a reduction in the BrdU-labelled
S-phase cell population and an increase in the
BrdU-labelled G2/M-phase cell population after ganete-
spib treatment (Fig. 2c).
Upregulation of JAK-STAT signalling pathway after
acquiring resistance to HSP90i
In order to obtain a global signature of differentially
expressed genes in TNBC cells after acquiring resistance
to ganetespib, whole transcriptome profiling with RNA-
seq was performed in the parental Hs578T cells and
both HSP90i-resistant clones CR2 and CR3 (Fig. 3). Dif-
ferential gene expression analysis showed that more than
1000 transcribed genes were significantly upregulated in
the HSP90i-resistant clones when compared to the
parental Hs578T cells. Most of the upregulated genes
were overlapping between the two clones, suggesting
similar mechanisms of resistance to HSP90i. Pathway
enrichment analysis on the significantly upregulated
genes revealed a diverse activation of signalling pathways
that could potentially mediate acquired resistance to
ganetespib in the HSP90i-resistant clones, notably 4 out
of the top 20 enriched pathways were linked to Janus
kinase-signal transducer and activator of transcription
(JAK-STAT) signalling pathway (Fig. 3 and Additional file 1:
Table S1). Several genes of the JAK-STAT signalling path-
way were upregulated in the HSP90i-resistant clones, in-
cluding cytokine IL6 and oncogenic transcription factor
MYC (Fig. 4a). ELISA assays showed that the medium of
both HSP90i-resistant clones expressed significantly
higher levels of IL6 compared to the parental Hs578T
cells, either in the absence or presence of ganetespib
(Fig. 4b). These data demonstrate that activation of
the JAK-STAT pathway, possibly mediated by autocrine
IL6 signalling, is associated with acquired resistance to
HSP90i in TNBC cells. Of interest, pSTAT3 levels corre-
lated with intrinsic resistance to HSP90i in TNBC cells
used in this study (Additional file 2: Figure S1).
Increased cytotoxicity of HSP90i with combined inhibition
of JAK-STAT signalling pathway
In order to identify potential novel targets for overcom-
ing acquired resistance to ganetespib in TNBC, a screen
with a 328-compound bioactive small molecule library
was performed on the parental Hs578T cell line and
HSP90i-resistant clone CR3. The library (n = 328)
covered a broad range of established targets in cancer
therapy, which were mostly approved for clinical use, or
in late stage clinical trial or preclinical development.
CR3 cells did not show selective sensitivity (Z-score ≥ 2)
to any compounds when compared with the parental
Hs578T cells, but showed selective resistance (Z-score ≤
− 2) to 20/328 compounds, which were mainly targeting
proteins involved in proliferation and cell cycle check-
points (Fig. 5a and Additional file 3: Table S2).
The screen with HSP90i-resistant clone CR3 was also
carried out, in the absence or presence of ganetespib
(10 nM) to identify compounds with selective combin-
ation effects. CR3 cells showed selective sensitivity
(See figure on previous page.)
Fig. 1 Anti-cancer activities of HSP90 inhibition in TNBC cells. a Differential sensitivity of ganetespib in TNBC cell lines. A panel of seven TNBC cell lines
(HS578T, MDA-MB-453, MDA-MB-468, MDA-MB-231, HCC 1937, BT20 and HCC1143) were treated with increasing concentrations of ganetespib for 72 h
and subjected to resazurin-based cell viability assay. Cell viability (%) for each treatment was expressed relative to the DMSO-treated control. Representative
graph from at least three independent experiments each performed in triplicate and error bars indicate SEM. IC50 (the drug concentration that reduces cell
viability to 50% of control) was calculated from the three independent experiments for each cell line. b Downregulation of HSP90 client proteins and
induction of apoptosis by ganetespib. HS578T, MDA-MB-231 and HCC1143 cell lines were treated with increasing concentrations of ganetespib (10, 30 and
100 nM) for 24 h. Protein lysates of the treated cells were subjected to western blotting analysis and blotted with the indicated antibodies. Cleaved PARP
was used to assess apoptosis and Hsp70 was used as a pharmacological marker for inhibition of Hsp90 activity. PPIB was used as loading control. c
Generation of HSP90i-resistant clones. Hs578T cells (105) were plated and treated with 30 nM of ganetespib. After 6 weeks, colonies started to form and
two independent clones (CR2 and CR3) were picked from different plates
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(Z-score ≥ 2) to 10/328 compounds, in the presence of
ganetespib. In contrast 5/328 compounds were selectively
cytotoxic to CR3 in the absence of ganetespib (Z-score ≤
− 2) (Fig. 5b and Additional file 4: Table S3). LY2784544,
which is an inhibitor of the Janus Kinase 2 (JAK2), was
among the most significant hits from the screen upon
retesting in CR3 as well as in the other HSP90i-resistant
clone CR2. The IC50 values of LY2784544 in CR2 and
CR3 cells were significantly decreased by 3.5- and 2.9- fold
respectively, in the presence of ganetespib (Fig. 6a). There
was also a significant decrease in IC50 values of ganetespib
in CR2 and CR3 cells by 2.3- and 2.7- fold respectively,
with the presence of LY2784544 (Fig. 6b).
In both HSP90i-resistant clones, western blotting ana-
lysis showed that LY2784544 treatment alone or in com-
bination caused a marked reduction in the expression
levels of pSTAT3 (Y705), which is downstream of JAK
(Fig. 6c) confirming inhibition of JAK-STAT signalling
pathway by LY2784544. Combined treatment of ganete-
spib and LY2784544 induced increased apoptosis and
further upregulation of HSP70 expression in the
HSP90i-resistant clones, suggesting an increase in cyto-
toxic activity of HSP90i with JAK2 inhibition despite
prior acquired resistance to HSP90i (Fig. 6c). Combined
treatment with another JAK2 inhibitor, (AZD1480) also
showed significantly increased sensitivity in both
HSP90i-resistant clones (Fig. 6d). These data further
suggest that the combined inhibition had a synergistic
effect on the HSP90i-resistant clones, despite prior ac-
quired resistance to HSP90i.
Discussion
Targeting HSP90 is a promising approach for the develop-
ment of novel therapeutics for TNBC patients, a subtype
of breast cancer with poor prognosis and lack of approved
targeted therapies. In accordance with previous reports in
TNBC [26, 27], we demonstrate that HSP90i using ganete-
spib caused inhibition of cell viability, downregulation of
client proteins, induction of apoptosis and G2/M cell cycle
arrest in TNBC.
Resistance to targeted therapies remains a major chal-
lenge in the treatment of cancer patients [34]. Increased
expression of HSP70 is associated with reduced sensitiv-
ity to HSP90i in prostate and colon cancer cells [35, 36].
Reduced expression of NQO1 is associated with resist-
ance to geldanamycin-based HSP90i such as 17-AAG
and 17-DMAG, but not to structurally unrelated HSP90i
in glioblastoma, oesophageal and breast cancer cells
[37–39]. Glucuronidation via increased UGT1A expres-
sion levels is associated with resistance to
resorcinol-based HSP90i such as ganetespib in colorectal
cancer cells [40, 41]. Loss in MCL dependency is associ-
ated with resistance to HSP90i in cancer cells and they
require a combined treatment with inhibition of BCL
family proteins for induction of apoptosis [42].
The mechanisms of resistance to HSP90i in TNBC is
not yet fully known. In this study, two independent
HSP90i-resistant clones were established as an in vitro
model to investigate the underlying mechanisms to
HSP90i resistance in TNBC cells. The clones showed
significant resistance to ganetespib and cross-resistance
to other HSP90i compared to parental cells. Gene
expression profiling and pathway analysis on the
HSP90i-resistant clones suggested that activation of the
survival JAK-STAT signalling pathway, possibly through
autocrine IL6 signalling, might be involved in the ac-
quired resistance to HSP90i in TNBC cells. The drug
screen also suggested that combined inhibition of
HSP90 and the JAK-STAT signalling pathway was able
to increase the cytotoxic activities of HSP90i and over-
come the acquired resistance to HSP90i in the cells. A
previous study in myeloproliferative cells also showed
that combination of HSP90i (NVP-AUY922) and JAK2
inhibitor (TG101209) induced the downregulation of
JAK2 signalling proteins and apoptosis [43].
The JAK-STAT signalling pathway is involved in pro-
moting oncogenesis, including cell proliferation, invasion,
inflammation and immune response [44, 45]. Feedback ac-
tivation of STAT3 causes resistance to various targeted
therapies (HER2, EGFR, MEK) and chemotherapies by re-
storing cell survival and proliferation [46, 47]. Increased
(See figure on previous page.)
Fig. 2 Resistance to HSP90i in CR2 and CR3. a Cross-resistance to HSP90i. Hs578T, CR2 and CR3 cells were treated with increasing concentrations
of either ganetespib, NVP-AUY922 or 17-AAG for 72 h and subjected to resazurin-based cell viability assay. Cell viability (%) for each treatment was
expressed relative to the DMSO-treated control. Representative graph from at least three independent experiments each performed in triplicate
and error bars indicate SEM. The table represents the IC50 values of compounds in the cell lines. The IC50 values in respective clones were
compared with the values in the parental Hs578T cells. *, *** and **** indicate p-value ≤0.05, ≤0.001 and≤ 0.0001 respectively; by Student’s t-test.
b Absence of downregulated expression of HSP90 client protein and induction of apoptosis. Hs578T, CR2 and CR3 cells were treated with 30 nM
ganetespib for 24 h. Lysates were subjected to western blotting analysis and blotted with indicated antibodies. Level of cleaved PARP was also
determined to assess apoptosis. PPIB and β-actin were used as loading controls. Representative images from two experiments are shown. c G2/M
cell cycle arrest observed in parental Hs578T cells only. Hs578T, CR2 and CR3 cells were treated with 30 nM ganetespib for 24 h and pulse labelled
with BrdU for 20 min. Cells were stained with propidium iodide and anti-BrdU antibody before analysed by flow cytometry. The top images
represent the cell population with BrdU staining and PI staining, which consist of G0/G1- (bottom left), G2/M- (bottom right) and S-phase. The
graph represents the mean percentage of cells in each phase of cell cycle from two independent experiments. Error bars indicate SEM
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levels of IL6 induce the expression of anti-apoptotic pro-
teins that inhibit apoptosis and promote proliferation in
cells, which in turn are associated to mediate resistance to
chemotherapy in prostate, breast and lung cancer cells
[48–51]. Interestingly, the HSP90i-resistant clones in our
study were also resistant to certain chemotherapies (adria-
mycin and mitoxantrone), suggesting that the upregulated
JAK-STAT signalling pathway might also be associated
with chemo-resistant in the TNBC cells.
Conclusions
This study demonstrates that the upregulated JAK-STAT
survival signalling pathway is associated with acquired
resistance to HSP90i in TNBC cells and that combined
therapy with JAK inhibition could overcome this resist-
ance. Our data suggest the possibility that identifying tu-
mours with low activity of JAK-STAT signalling pathway
could potentially be used for the selection of cancer pa-
tients that would most likely benefit to ganetespib.
(See figure on previous page.)
Fig. 3 Differential RNA expression in HSP90i-resistant clones compared to parental Hs578T cells. RNA samples from DMSO-treated and
ganetespib-treated Hs578T, CR2 and CR3 cells were analysed for whole transcriptome profiling with RNA-sequencing. Differential gene expression
analyses were performed between DMSO-treated parental Hs578T cells with either DMSO-treated CR2 or CR3 and the significantly upregulated
genes observed in these clones were mostly overlapping. Pathway enrichment analysis using Metacore™ was performed on the significantly
upregulated overlapping genes. The graph represents the top 20 most significantly upregulated pathways in the HSP90i-resistant clones, with
FDR (false discovery rate) value < 0.05. Pathways highlighted in blue are linked to JAK-STAT signalling
a b
Fig. 4 Upregulation of JAK-STAT signalling pathway in HSP90i-resistant clones. a Upregulation of genes involved in JAK-STAT signalling pathway.
Heatmap represents the significantly upregulated genes involved in the JAK-STAT signalling pathway in HSP90i-resistant clones CR2 and CR3
compared to parental Hs578T cells. The colour scale indicates the significant log2 FC (q-value ≤0.05) in gene expression for individual clones
compared to Hs578T cells from blue (− 4, downregulation) to red (+ 4, upregulation). b Increased IL6 expression in HSP90i-resistant clones CR2
and CR3. Media from Hs578T, CR2 and CR3 cells after treatment with ganetespib (30 nM) for 24 h were subjected to the ELISA assay in order to
measure the IL6 present in the media. The graph represents the mean IL6 concentration relative to DMSO-treated Hs578T cells from two
independent experiments each performed in duplicate. Error bars indicate SEM. IL6 levels were significantly higher in CR2 and CR3 than Hs578T
cells, where p values < 0.01 by two-way ANOVA with cell line and ganetespib treatment as factors. Ganetespib treatment did not significantly
affect IL6 levels in Hs578T, CR2 or CR3 cells
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Fig. 5 Differential sensitivity to compounds in parental Hs578T cells and HSP90i-resistant clone CR3. a Comparison between parental Hs578T cells
and CR3. A screen with a 328-compound bioactive small molecule library was performed on the parental Hs578T cells and HSP90i-resistant clone
CR3. The scatter plot represents the Z-scores comparing the sensitivity for individual compounds in Hs578T and CR3 cells. The Z-scores were
ranked from compound that was least sensitive to most sensitive in CR3 when compared with Hs578T cells. Z-score≥ 2 represents compounds
that were selectively cytotoxic to CR3 compared with Hs578T cells while Z-score≤ − 2 represents compounds that were selectively cytotoxic to
Hs578T cells compared with CR3. b Comparison between the presence and absence of ganetespib in CR3. The screen on CR3 was also
performed in the presence of ganetespib. The scatter plot represents the Z-scores comparing the sensitivity for individual compounds in CR3, in
the presence and absence of ganetespib. The Z-scores were ranked from compound that was least sensitive to most sensitive in CR3, in the
presence of ganetespib. Z-score≥ 2 represents compounds that were selectively cytotoxic to CR3 in the presence of ganetespib while Z-score≤
− 2 represents compounds that were selectively cytotoxic to CR3 in the absence of ganetespib
Fig. 6 Synergistic effects after combined inhibition of HSP90 and JAK2. a Increased sensitivity to JAK2 inhibition. HSP90i-resistant clones CR2 and
CR3 were treated with increasing concentrations of a JAK2 inhibitor, LY2784544 alone or in combination with 10 nM ganetespib for 72 h and
subjected to resazurin-based cell viability assay. Cell viability (%) for each treatment was expressed relative to either DMSO-treated or ganetespib
only-treated control for combination treatment. Representative graph from three independent experiments each performed in triplicates and
error bars indicate SEM. b Increased sensitivity to HSP90i. HSP90i-resistant clones CR2 and CR3 were treated with increasing concentrations of
ganetespib alone or in combination with 1 μM LY2784544 for 72 h and subjected to resazurin-based cell viability assay. Cell viability (%) for each
treatment was expressed relative to either DMSO-treated or LY2784544 only-treated control for combination treatment. Representative graph
from three independent experiments each performed in triplicates and error bars indicate SEM. c Inhibition of JAK-STAT signalling pathway and
induction of apoptosis after combined treatment. HSP90i-resistant clones CR2 and CR3 were treated with ganetespib (10 nM), LY2784544 (1 μM)
or in combination for 24 h. Protein lysates were analysed by western blotting and blotted with pSTAT3 (Y705), which is a downstream protein of
the JAK signalling pathway. Levels of cleaved PARP and HSP70 were also determined to assess apoptosis and pharmacodynamic marker for
HSP90i respectively. PPIB was used as loading control. d Increased cytotoxicity after combined treatment. HSP90i-resistant clones CR2 and CR3
were also treated with another JAK2 inhibitor, AZD1480 (2 μM) alone or in combination with ganetespib (10 nM) for 72 h and subjected to
resazurin-based cell viability assay. The graph represents the overall mean cell viability (%) relative to DMSO-treated or ganetesib-treated control
from two independent experiments each performed in triplicates. Error bars indicate SEM. The sensitivity to AZD1480; in the absence or presence
of ganetespib were compared in the HSP90i-resistant clones. ** and *** indicate p values ≤0.01 and≤ 0.001 respectively; by Student’s t-test
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Additional file 1: Table S1. The top 20 most significantly enriched
pathways seen in HSP90i-resistant clones. Pathway enrichment analysis
performed on differentially expressed genes in parental and HSP90i-resistant
Hs578T cells using MetaCore (https://portal.genego.com). (DOCX 13 kb)
Additional file 2: Figure S1. Positive correlation of pSTAT3 expression
with HSP90i sensitivity. A scatter plot displaying the relationship between
ganetespib sensitivity (IC50) and pSTAT3 expression in the panel of TNBC
cell lines. (DOCX 25 kb)
Additional file 3: Table S2. Compounds that were selectively cytotoxic
to parental Hs578T cells compared with HSP90i-resistant clone CR3. Cell
viability was assessed after 72 h exposure to a 326-compound small
molecule library (1 μM each compound. SELLECK). Z-scores ≤ − 2 identi-
fied compounds that were selectively cytotoxic to parental Hs578T cells.
(DOCX 13 kb)
Additional file 4: Table S3. Compounds that were differentially
cytotoxic to HSP90i-resistant clone CR3 in the presence of ganetespib.
Cell viability was assessed after 72 h exposure to a 326-compound small
molecule library (1 μM each compound. SELLECK) in the presences or
absence of ganetespib (10 nM). Z-scores ≤ − 2 identified compounds that
were selectively cytotoxic CR3 cells in the absence of ganetespib, Z-
scores ≥2 identified compounds that were selectively cytotoxic CR3 cells
in the presence of ganetespib. (DOCX 23 kb)
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